On September 23, 2024, SciSparc Ltd. announced FDA approval to begin a Phase IIb clinical trial for a treatment of Tourette Syndrome. This event is seen as significant for the company, indicating a positive sentiment for investors.
AI Assistant
SCISPARC LTD
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.